Depo-Provera Lawsuit: Brain Tumor Claims

Depo-Provera (medroxyprogesterone acetate) is a contraceptive injection that French and global research now links to a significantly elevated risk of meningioma — a type of brain or spinal tumor. Thousands of women are filing a Depo-Provera lawsuit against Pfizer and its subsidiaries, alleging the companies knew about the risk and failed to warn patients.

What Is Depo-Provera?

Depo-Provera is an injectable form of progestin — specifically medroxyprogesterone acetate — given as a contraceptive shot every three months. The U.S. Food and Drug Administration first approved it in 1992. Pfizer markets it in the United States under the Depo-Provera and Depo-SubQ Provera 104 brand names.

More than 4 million American women have used the injection at some point. It is also widely prescribed for endometriosis, abnormal uterine bleeding, and certain hormone-sensitive cancers. Many patients received injections for years, sometimes more than a decade, without any warning about tumor risk.

Unlike daily pills or long-term implants that users can stop on their own, Depo-Provera injections build up in the body. The hormone level remains elevated for months after the last dose. That prolonged exposure is now at the center of litigation. To understand how these cases are organized, see our overview of mass torts.

The Meningioma Link: What the Science Shows

A landmark French study published in the British Medical Journal in March 2024 found that high-dose progestin use was associated with a dramatically increased risk of intracranial meningioma. Researchers analyzed data from more than 18,000 women across France's national health database. Women who used medroxyprogesterone acetate for one year or more faced a risk of meningioma approximately 5.6 times higher than non-users.

Meningiomas are tumors that form in the meninges — the membranes surrounding the brain and spinal cord. Most are not cancerous in the traditional sense, but they press on brain tissue. Symptoms include chronic headaches, vision changes, hearing loss, seizures, memory loss, and weakness on one side of the body.

The French national medicines agency (ANSM) acted quickly after the study. It restricted certain high-dose progestins in France and required updated labeling. In the United States, the FDA issued a Drug Safety Communication in January 2025 requiring Pfizer to add a black-box warning about meningioma risk to the Depo-Provera label.

A separate 2022 study published in PLOS Medicine also found elevated meningioma risk among progestin users, adding independent weight to the French findings. The convergence of data from multiple countries and research teams is a key factor driving the Depo-Provera lawsuit wave.

Who May Qualify for a Depo-Provera Lawsuit?

You may qualify for a Depo-Provera brain tumor lawsuit if you received medroxyprogesterone acetate injections and were later diagnosed with a meningioma. Most attorneys currently evaluating these claims look for a combination of factors. No two cases are identical, but several common criteria apply.

Core Eligibility Criteria

The first factor is documented Depo-Provera use. Prescription records, pharmacy fill records, or medical notes confirming injections are the strongest evidence. Second, you need a meningioma diagnosis from a licensed medical provider, confirmed by imaging such as MRI or CT scan, or by pathology after surgical removal.

Third, most attorneys focus on duration. Women who received injections for 12 months or more appear to carry the highest statistical risk based on available studies. Shorter use periods may still qualify depending on individual facts and the jurisdiction. Check your eligibility now to get a preliminary assessment.

Who Is Currently Being Excluded

Cases where the meningioma predates any Depo-Provera use are generally not viable. Claims where no medical documentation of injection use exists face serious evidentiary hurdles. Women whose tumors were found incidentally and never caused symptoms may also face challenges establishing damages.

What the Lawsuits Allege

Plaintiffs in the Depo-Provera lawsuit allege that Pfizer knew or should have known about the meningioma risk decades before the FDA required a warning. The core legal theories are failure to warn, negligent misrepresentation, and strict products liability. Some suits also allege fraud for actively concealing safety data.

Internal documents produced in early discovery reportedly show that Pfizer scientists were aware of progestin-tumor interactions as early as the late 1990s. Plaintiffs argue that a timely warning would have allowed women and their doctors to choose alternative contraception. Instead, many women continued injections for years while tumors grew silently.

The harm extends beyond the tumor itself. Meningioma treatment often requires brain surgery, which carries risks of permanent neurological damage. Radiation therapy can follow surgery. Some women experience lasting cognitive impairment, disability, or loss of employment as a direct result.

Mass Tort vs. Class Action: Key Differences

Depo-Provera brain tumor cases are being pursued as mass torts, not class actions — and that distinction matters enormously for how much compensation individual plaintiffs can receive.

Because meningioma cases involve dramatically different injury levels — a small tumor requiring monitoring versus a large tumor requiring emergency surgery — mass tort structure allows each case to be valued on its own merits. A plaintiff who needed two brain surgeries and lost her job will likely receive far more than a plaintiff whose tumor was found early and monitored without treatment.

Settlement Outlook and Litigation Status

As of June 2026, the Depo-Provera meningioma litigation is in active pretrial consolidation in federal multidistrict litigation (MDL). No global settlement has been announced yet. However, pharmaceutical MDLs of this scale typically settle before any individual case reaches a jury trial.

The MDL process works through bellwether trials — a small number of representative cases that go to verdict first. Those verdicts give both sides data to negotiate a global resolution. In past pharmaceutical mass torts, the first bellwether verdicts often trigger settlement talks within 12 to 18 months.

Estimated settlement ranges in the legal community vary widely at this early stage. Cases involving surgical removal of a large meningioma with documented neurological injury tend to draw the highest valuations. Cases where the tumor was small and treated conservatively typically draw lower figures. No official estimates should be relied upon until the MDL produces bellwether outcomes.

Statute of Limitations: Time Limits Matter

The statute of limitations for a Depo-Provera lawsuit varies by state, but most personal injury statutes run two to three years from the date of injury or discovery of the injury. In a drug-injury case, the clock often starts when you received your diagnosis — not when you took the drug.

Some states apply a discovery rule, which means the clock starts when a reasonable person would have connected the drug to the injury. Because meningioma warnings were not required until January 2025, some plaintiffs may have grounds to argue the discovery clock did not start until they learned of the FDA warning or linked their diagnosis to Depo-Provera use.

Do not assume you have missed the deadline without speaking to an attorney. Missing the filing window is the single most common reason viable claims are lost. Acting quickly preserves your rights regardless of where the statute ultimately falls.

Evidence to Preserve Right Now

Preserving documentation now is one of the most important steps any potential plaintiff can take. Evidence degrades, medical records get archived, and pharmacies purge fill histories after a set number of years.

Medical Records

Request your complete medical records from every provider who administered Depo-Provera injections. Also gather records from any neurologist, neurosurgeon, or radiation oncologist who treated your meningioma. MRI and CT scan images — not just the written reports — should be preserved on disc or digital download.

Pharmacy Records

Contact your pharmacy or pharmacies and request a complete fill history going back as far as records exist. Chain pharmacies typically keep digital records for 10 years. Independent pharmacies vary. A fill history showing the dates, doses, and number of injections can establish duration of use — a critical element in these cases.

Financial and Employment Records

Document any out-of-pocket medical expenses, lost wages, or changes in employment status linked to your diagnosis or treatment. Receipts, pay stubs, tax returns, and employer letters all help build the damages picture. Keep a written account of how your daily life has changed since diagnosis.

The Defective Product Basis for These Claims

Depo-Provera lawsuits rest primarily on a failure-to-warn theory, which is one of the three main types of defective product claims recognized in U.S. tort law. A product is defective in its warnings when the manufacturer knows of a material risk and fails to disclose it adequately to users or prescribers.

Pfizer had a legal duty to update Depo-Provera's label as new safety signals emerged. Plaintiffs argue the company had enough information by the mid-2000s to at minimum investigate meningioma risk, and that the delay between early scientific signals and the 2025 black-box warning represents a years-long failure of that duty.

A secondary theory is manufacturing or design defect — arguing that the drug's progestin potency, dose schedule, or formulation was itself unreasonably dangerous for long-term use. This theory is harder to prove but is included in many complaints as an alternative basis for liability.

Courts applying strict liability do not require plaintiffs to prove that Pfizer acted intentionally or recklessly. The standard asks whether the product was unreasonably dangerous without adequate warnings at the time it was sold. Given the FDA's own January 2025 action, plaintiffs have a strong baseline argument that warnings were inadequate for decades.

Next Steps If You Were Harmed

If you used Depo-Provera and received a meningioma diagnosis, the most important action you can take right now is to gather your records and speak with an attorney who handles pharmaceutical mass torts. Most law firms evaluating these cases offer free consultations and work on a contingency fee — meaning you pay nothing unless you recover.

Do not sign any release or accept any payment from Pfizer or its insurers without independent legal advice. Early settlement offers from defendants in mass tort litigation often undervalue individual claims before the full scope of harm is established.

You can also check your eligibility on this site to get a preliminary assessment based on your use history and diagnosis. That information will help you have a more productive first conversation with an attorney.

Frequently Asked Questions

What is a Depo-Provera lawsuit?

A Depo-Provera lawsuit is a personal injury claim filed against Pfizer alleging that the company failed to warn patients about the risk of meningioma — a type of brain or spinal tumor — linked to long-term use of the injectable contraceptive medroxyprogesterone acetate. These cases are being organized as a mass tort in federal court.

What type of brain tumor is linked to Depo-Provera?

The tumor type specifically linked to Depo-Provera use is meningioma — a tumor that grows in the meninges, the membranes surrounding the brain and spinal cord. Most meningiomas are not classified as malignant, but they can cause serious harm by pressing on brain tissue and disrupting normal neurological function.

How long did someone have to use Depo-Provera to be at risk?

The 2024 BMJ study found the highest risk among women who used medroxyprogesterone acetate for 12 months or more. Women in that group faced approximately 5.6 times the meningioma risk of non-users. Some researchers believe even shorter periods carry elevated risk, but current litigation is focused primarily on patients with at least one year of documented use.

Did the FDA warn about this risk?

Yes. The FDA issued a Drug Safety Communication in January 2025 requiring Pfizer to add a black-box warning — the agency's most serious warning category — to Depo-Provera labeling about the risk of meningioma. Plaintiffs argue this warning came years after the company had access to data signaling the risk.

Is there already a settlement for Depo-Provera brain tumor cases?

No global settlement has been reached as of June 2026. The cases are in active MDL pretrial proceedings. Settlements in pharmaceutical mass torts typically follow bellwether trials, which have not yet occurred in this litigation. Filing now places you in the queue and preserves your legal rights.

How much could a Depo-Provera lawsuit be worth?

Settlement values vary significantly based on injury severity, duration of drug use, treatment required, and documented damages such as lost income or disability. Cases involving surgical removal of a large meningioma with lasting neurological effects tend to carry higher values. No reliable estimates exist until bellwether verdicts establish a baseline.

Can I still file if my meningioma was diagnosed years ago?

Possibly yes. Many states apply a discovery rule that starts the statute of limitations when you learned — or reasonably should have learned — that Depo-Provera caused your tumor. Because the FDA did not require a meningioma warning until January 2025, some plaintiffs diagnosed years earlier may still be within the filing window. Speak with an attorney to evaluate your specific timeline.